iobiotech.com (IOBT): Price-to-Projected Revenue Ratio

IOBT (IO Biotech Inc) - company brandmark

The forward P/S dynamics on the GURU.Markets chart reflect revenue expectations from the sale of IO102-IO103 cancer vaccines. Innovative developments by IO Biotech, Inc. (IOBT) break down tumor defense barriers, enhancing overall therapy. However, the lack of profitable products leaves the company dependent on external financing, and the mark indicates the current state of this investment balance.

IOBT IO Biotech Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for IO Biotech Inc. (IOBT)

- stock price and consensus target price:
Stock Quotes IO Biotech|IOBT - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value IO Biotech Inc.|IOBT - Business Value
- book value of equity indicators:
Net Assets per Single Share IO Biotech|IOBT - Total Stockholders' Equity|Market Cap to Net Assets Ratio iobiotech.com|IOBT - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio IO Biotech, Inc.|IOBT - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital IO Biotech, Inc.|IOBT - Aggregate Debt Obligations|Debts to Book Capitalization IO Biotech Inc.|IOBT - Long-Term Debt|Company Short-Term Debt IO Biotech|Quick Ratio iobiotech.com
- business earnings and investment ratios data:
IOBT - Net Profit|Expected Profit IO Biotech, Inc.|IOBT - Market Cap to Net Income|Projected Price to Earnings IO Biotech Corp|IOBT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple IO Biotech Inc.|IOBT - Operating income before deduction of amortization|Earnings per share for the last twelve months IO Biotech|IOBT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months iobiotech.com|IOBT - Earnings per share increase in current year|Earnings growth forecast for next year IO Biotech, Inc.
- revenue and sales details:
IOBT - Company Revenue|Projected Sales Volume IO Biotech|IOBT - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio IO Biotech Inc.
Summary company analysis:IO Biotech IOBT
Manufactured products of IO Biotech Inc.

IO Biotech, Inc. (IOBT) maintains a strong position in the development of anti-tumor vaccines, leveraging the trust of U.S. and Danish scientists. The expected revenue multiple compares the current market value of the business with projected income, allowing investors to quickly assess the fair value of the asset relative to the prospects of metastasis therapy without waiting for quarterly reports, as this chart reflects.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|Sutro Biopharma, Inc - Forward Price to Sales|INKT (MiNK Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Werewolf|Price-to-Projected Revenue Ratio Immix Biopharma, Inc. (IMMX)|ALXO: Future Price to Revenue|Cue Biopharma, Inc. - Forward Price-to-Revenue Multiple|PDS Biotech (PDSB) - Market Cap to Future Revenue Ratio|Sonnet BioTherapeutics Holdings Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio MAIABiotech.com MAIA|Liminatus Pharma LLC (LIMN) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio LAVA Therapeutics (LVTX)|Forward Price-to-Revenue Multiple NXTC|LPTX: Forward Price to Sales|Forward P/S Multiple INTS|Price-to-Projected Revenue Ratio SNSE (senseibio.com)|Forward P/S Multiple TOVX (Theriva Biologics)|Market Cap to Expected Sales Ratio Gritstone bio Inc. (GRTS)|KA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio NexImmune Corporation|TSBX (turnstonebio.com) - Forward Price-to-Revenue Multiple|VCNX: Price to Expected Revenue Ratio|HARP (Harpoon Therapeutics, Inc.) - Forward P/S Multiple